翰思艾泰-B(03378.HK)预计12月23日上市 引入富德生命人寿保险等多家基石

Group 1 - The company, Hansai Aitai-B (03378.HK), plans to globally offer 18.321 million H-shares, with 1.8321 million shares available in Hong Kong and 16.4889 million shares for international offering, subject to reallocation and the exercise of the over-allotment option [1] - The expected pricing range for the shares is HKD 28.00 to HKD 32.00 per share, with the shares anticipated to begin trading on December 23, 2025 [1] - The company specializes in biotechnology with expertise in structural biology, translational medicine, and clinical development, having developed a product pipeline that includes one core product and nine other candidate products [1] Group 2 - The core product, HX009, is a self-developed anti-PD-1/SIRPα dual-function antibody fusion protein, with Phase I clinical trials completed in Australia and China [2] - Currently, three clinical projects for HX009 are ongoing in China, targeting advanced melanoma, relapsed/refractory Epstein-Barr virus-positive non-Hodgkin lymphoma, and advanced biliary tract cancer [2] - The company received approval from the National Medical Products Administration for a combination study of HX009 with trastuzumab for advanced triple-negative breast cancer, with patient recruitment expected to complete by 2026 [2] Group 3 - The company has established cornerstone investment agreements, with cornerstone investors agreeing to subscribe for a total of 2.9178 million shares at the maximum offer price of HKD 32.00 per share [3] - Key cornerstone investors include Fude Resources Investment Holdings Group, Sage Partners Master Fund, and Guotai Junan Securities Investment (Hong Kong) Limited, among others [3] Group 4 - Assuming no over-allotment option is exercised, the company expects to net approximately HKD 496.3 million from the global offering at an indicative offer price of HKD 30.00 per share [4] - The net proceeds are planned to be allocated as follows: approximately 35% for the development of the core product HX009, 33% for the main products HX301 and HX044, 17% for other important product development, 5% for commercialization and business development activities, and 10% for working capital and general corporate purposes [4]